Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study

• Published in: Rheumatology international Vol. 41; no. 11; pp. 1905 - 1913
• Main Authors: Naffaa, Mohammad E., Hassan, Fadi, Golan-Cohen, Avivit, Merzon, Eugene, Green, Ilan, Saab, Amir, Paz, Ziv
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2021; Springer Nature B.V
• Subjects: Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Biological Products - therapeutic use; Cohort analysis; Cohort Studies; Comorbidity; Databases, Factual; Female; Humans; Israel; Longitudinal Studies; Male; Medicine; Medicine & Public Health; Middle Aged; Population-based studies; Retrospective Studies; Rheumatoid arthritis; Rheumatology; Sex Factors; Time Factors; Israel; Drug survival factors; Disease-modifying antirheumatic drugs; Rheumatoid arthritis; Biologic therapy

Lack of sufficient head-to-head trials comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA), makes the choice of the first bDMARD a matter of rheumatologist’s preference. Longer drug survival on the first bDMARD usually correlates with early remission. We a...